Allo-Stem Cell Delivered Oncolytic Viro-Immunotherapy for Glioma & Ovarian Cancer: Bench to Bedside
Time: 4:30 pm
day: Conference Day One
Details:
- Discussing the unique approach of using tumor-tropic NSCs as delivery vehicles of oncolytic viruses
- Discuss current multi-dose, multi-site glioma clinical trial and planned 2026 ovarian cancer clinical trials using this approach
- Manufacturing overview
